NCT00473005View on ClinicalTrials.gov

Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

PHASE1TerminatedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Breast Cancer

Interventions

DRUG

Capecitabine

825 mg/m2 bid, Oral

DRUG

RAD001

2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Stanford University

OTHER